Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Z-Cube, a venture of Italy-based Zambon Company, and Yissum Research Development Company of Israel have signed a license agreement for Z-Cube to develop and commercialise a nanotechnology drug delivery system for the treatment of pain.
Subscribe to our email newsletter
As per the deal, Z-Cube will sponsor a research program to be conducted by Prof. Touitou and her group. Z-Cube will have worldwide exclusive rights to develop and commercialize the technology for pain applications while Yissum will receive license fees, milestones and royalty payments. In addition, Z-Cube will have the right to grant sublicenses.
israel-based Yissum Research Development Company has registered 6100 patents covering 1750 inventions; has licensed out 480 technologies and has spun out 65 companies.
Z-Cube – Zambon Company S.p.A. is engaged innthe business of Drug Delivery System (DDS) exploitation. Z-Cube invests in and validates early stage innovative DDS with the potential to generate new products in selected therapeutic areas, with the opportunity to generate NewCos.